April 18, 2022 11:24 AM EDT
Pharma
Law

Bris­tol My­ers inks $11M deal to set­tle an­ti­com­pet­i­tive claims in HIV suit

Nicole DeFeudis

Editor

Three years ago, AIDS ac­tivists filed a law­suit ac­cus­ing Bris­tol My­ers Squibb, Gilead, and John­son & John­son of schem­ing to block gener­ic HIV med­i­cines from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Lex­i­con ends com­mer­cial work to fo­cus on R&D

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times